Pre-Clinical Results for ALN-AGT Presented at AHA Scientific Sessions

Pre-Clinical Results for ALN-AGT Presented at AHA Scientific Sessions

We presented new pre-clinical results for ALN-AGT, a subcutaneously administered RNAi therapeutic development candidate targeting angiotensinogen (AGT) for the treatment of hypertensive disorders of pregnancy (HDP), including preeclampsia, at the American Heart Association Scientific Sessions 2017 in Anaheim.

View the poster

The data demonstrate that ALN-AGT ameliorated the clinical sequelae of preeclampsia in rodent models, and improved the outcome of the fetus. 



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.